Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and MACLO/IVAM Chemotherapy With Thalidomide Maintenance in Untreated Mantle Cell Lymphoma
NCT00450801Phase 2Completed
- Sponsor
- University of Miami
- Start
- Apr 2004
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Targeted Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, pegylated liposomal doxorubicin, cyclophosphamide, folinic acid and 6 more in mantle cell lymphoma (MCL), sponsored by University of Miami. Primary endpoint: Progression-Free Survival up to 5 years. Started Apr 2004; status: completed.
02
Drugs
rituximabmethotrexatepegylated liposomal doxorubicincyclophosphamidefolinic acid
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00450801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450801.